Background: The “Nefertiti lift” consists of injecting the platysmal bands and the inferior border of the mandible with botulinum toxin. No clinical trial has evaluated its effect on the different lower face and neck aging components, and little is known about the clinical characteristics that predict treatment success.
Methods: Patients were injected with abobotulinumtoxinA along the inferior border of the mandible and into the platysmal bands. Using standardized preinjection and postinjection photographs, the jowls, marionette lines, oral commissures, neck volume, and platysmal bands at maximal contraction and at rest were assessed with validated photonumeric scales. In addition, the overall appearance of the lower face and neck was evaluated by the Investigators and Subjects Global Aesthetic Improvement Score. Pain and patient satisfaction rates were also evaluated.
Results: Thirty patients were injected with a mean dose of 124.9 U of abobotulinumtoxinA per patient. Platysmal bands at rest and with maximal tension reached a statistically significant improvement. The other components showed a tendency for improvement but did not reach statistical significance; 93.3 percent of investigators and patients rated the overall results as improved, and 96.6 percent of patients were satisfied with their results. When comparing the patients who improved the most to all the other patients, they had lower preinjection region-specific scores.
Conclusions: The Nefertiti lift can be used on its own or in conjunction with other rejuvenating procedures. It is particularly helpful in younger patients with platysma muscle hyperactivity and retained skin elasticity.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
Beirut, Lebanon
From the Departments of Plastic and Reconstructive Surgery and Dermatology, Faculty of Medicine, Saint-Joseph University Hotel Dieu de France Hospital.
Received for publication October 7, 2016; accepted November 22, 2016.
The study is registered under the name “Botulinum Toxin for Neck Rejuvenation,” ClinicalTrials.gov identification number NCT02864511 (https://clinicaltrials.gov/ct2/show/NCT02864511).
Disclosure: The authors have no financial information to disclose. No funding was received for the article.
Supplemental digital content is available for this article. Direct URL citations appear in the text; simply type the URL address into any Web browser to access this content. Clickable links to the material are provided in the HTML text of this article on the Journal’s website (www.PRSJournal.com).
Samer F. Jabbour, M.D., Faculty of Medicine, Saint-Joseph University Hotel Dieu de France Hospital, Alfred Naccache Boulevard, Achrafieh, Beirut 1100 2160, Lebanon, samermed@gmail.com
